OpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Up 0.9 %

OPGN stock opened at $3.30 on Friday. OpGen has a fifty-two week low of $1.65 and a fifty-two week high of $38.40. The business has a 50-day moving average of $5.46 and a 200-day moving average of $4.69.

Institutional Trading of OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp purchased a new stake in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent quarter. 2.68% of the stock is currently owned by hedge funds and other institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.